UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549
                                -----------------

                                    FORM 10Q
                                -----------------
(Mark One)

 [ X ]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
            EXCHANGE ACT OF 1934
                   For the quarterly period end March 31, 2013

[ ]         TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE
            ACT

             For the transition period from __________ to ___________

                        Commission file number: 000-50294

                        LEGACY TECHNOLOGY HOLDINGS, INC.
                        --------------------------------
             (Exact name of registrant as specified in its charter)

         Colorado                                      84-1426725
         --------                                      ----------
(State of Incorporation)                         (IRS Employer ID Number)

                    7609 Ralston Road, Arvada, Colorado 80002
                    -----------------------------------------
                    (Address of principal executive offices)

                                  303-422-8127
                                  ------------
                         (Registrant's Telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the past 12 months (or for such shorter  period that the registrant was required
to file such reports),  and (2) has been subject to the filing  requirements for
the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted  electronically  and
posted on its corporate Web site, if any, every  Interactive  Data File required
to be submitted and posted  pursuant to Rule 405 for Regulation S-T  (ss.232.405
of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes [ ] No []

Indicate by check mark whether the  registrant is a large  accelerated  file, an
accelerated filer, a non-accelerated  filer, or a smaller reporting company. See
the definitions of "large accelerated  filer,"  "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large  accelerated  filer [ ] Accelerated  filer [ ]  Non-accelerated  filer [ ]
Smaller reporting company [X] (Do not check if a smaller reporting company)


<PAGE>



Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Indicate  the number of share  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

As of June 27, 2013,  there were  3,731,772  shares of the  registrant's  common
stock issued and outstanding.




<PAGE>
<TABLE>
<CAPTION>
<S>                                                                                            <C>



PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements       (Unaudited)                                                Page
                                                                                               ----

         Balance Sheets -March 31, 2013 and
                  December 31, 2012 (Audited)                                                    F-1

         Statements of Operations  -
                  Three months ended March 31, 2013 and 2012 and
                  From May 8, 2008 (Inception) to March 31, 2013                                 F-2

         Statements of Changes in Shareholders' Deficit -
                   From May 8, 2008 (Inception) to March 31, 2013                                F-3

         Statements of Cash Flows -
                  Three months ended March 31, 2013 and 2012 and
                  From May 8, 2008 (Inception) to March 31, 2013                                 F-4

         Notes to the Financial Statements                                                       F-5

Item 2.  Management's Discussion and Analysis of Financial Condition
                  and Results of Operations                                                      1

Item 3.  Quantitative and Qualitative Disclosures About Market Risk
                  - Not Applicable                                                               3

Item 4. Controls and Procedures                                                                  3

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings -Not Applicable                                                       5

Item 1A.  Risk Factors -  Not Applicable                                                         5

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds                             5
                  -Not Applicable

Item 3.  Defaults Upon Senior Securities - Not Applicable                                        5

Item 4.  Mine and Safety Disclosures                                                             5

Item 5.  Other Information - Not Applicable                                                      5

Item 6.  Exhibits                                                                                6
SIGNATURES                                                                                       7
</TABLE>


<PAGE>




                                                                PART I

ITEM 1. FINANCIAL STATEMENTS



<PAGE>
<TABLE>
<CAPTION>

                 LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                           CONSOLIDATED BALANCE SHEETS
                                   (Unaudited)
<S>                                                                             <C>

                                                                                         March 31,           December 31,
                                                                                            2013                 2012
                                                                                      -----------------    -----------------
Assets
         Current Assets
                 Cash                                                                         $ 41,558                 $ 70
                                                                                      -----------------    -----------------
         Total Assets, all current                                                            $ 41,558                 $ 70
                                                                                      =================    =================

Liabilities and Stockholders' Deficit
         Current liabilities
                 Accounts payable                                                            $ 331,150            $ 325,229
                 Accrued expenses                                                              830,137              802,269
                 Advances payable                                                               41,456               68,956
                 Notes payable                                                                  31,632               31,632
                 Convertible notes payable                                                     699,000              630,000
                                                                                      -----------------    -----------------
         Total Current Liabilities                                                           1,933,375            1,858,086
                                                                                      -----------------    -----------------
Stockholders' Deficit
         Common stock, $0.0001 par value; 100,000,000 shares                                       373                  373
           authorized; 3,731,772  shares issued and outstanding
           at March 31, 2013 and December 31, 2012, respectively
         Additional paid-in capital                                                         (1,094,027)          (1,163,027)
         Deficit accumulated during the development stage                                     (798,163)            (695,362)
                                                                                      -----------------    -----------------
                 Total Stockholders' Deficit                                                (1,891,817)          (1,858,016)
                                                                                      -----------------    -----------------

Total Liabilities and Stockholders' Deficit                                                   $ 41,558                 $ 70
                                                                                      =================    =================

See the accompanying notes to these consolidated financial statements.

</TABLE>
                                       F-1

<PAGE>
<TABLE>
<CAPTION>


                 LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)
<S>                                                                             <C>



                                            For the Three Months Ended     May 8, 2008
                                                   March 31,             (Inception) to
                                               2013         2012         March 31, 2013
                                           ---------------------------  ------------------
Revenue:
       Sales                                        $ -           $ -                 $ -
                                           ---------------------------  ------------------

Operational expenses:
       General and administrative                 5,933        16,657             268,870
                                           ---------------------------  ------------------
             Total operational expenses           5,933        16,657             268,870
                                           ---------------------------  ------------------

Loss from operations                             (5,933)      (16,657)           (268,870)
                                           ---------------------------  ------------------

Other income (expense):
       Gain on debt relief                            -             -              68,005
       Finance cost of convertible notes        (69,000)            -             (69,000)
       Interest expense                         (27,868)      (27,777)           (528,298)
                                           ---------------------------  ------------------
             Total other expense                (96,868)      (27,777)           (529,293)
                                           ---------------------------  ------------------

Net Loss                                     $ (102,801)    $ (44,434)         $ (798,163)
                                           ===========================  ==================

Per share information
Net (loss) per common share
       Basic                                    $ (0.01)      $ (0.01)
       Fully diluted                              (0.01)        (0.01)
                                           ---------------------------

Weighted average number of common
       stock outstanding                      3,731,772     3,731,772
                                           ---------------------------



See the accompanying notes to these consolidated financial statements.


</TABLE>

                                      F-2
<PAGE>
<TABLE>
<CAPTION>


                 LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
                                   (Unaudited)
<S>                                                                             <C>


                                                                                                    Additional
                                                            Common Stock                             paid-in
                                                           Number of shares       Amount             Capital
                                                         -------------------   --------------    -----------------

Balances at December 31, 2006*                                            -              $ -                  $ -
Net income (loss) for the year                                            -                -                    -
                                                         -------------------   --------------    -----------------
Balances at December 31, 2007*                                            -                -                    -

Issuance of Founders common stock - cash                          4,800,000              480                5,120
Issuance of Founders common stock - services                      4,200,000              420                3,780
Stock issued for Net Liabilities - reverse merger                 1,007,003              101           (1,197,555)
Capital contribution - related party                                      -                -               25,000
Net income (loss) for the year                                            -                -                    -
                                                         -------------------   --------------    -----------------
Balance as of  December 31, 2008*                                10,007,003            1,001           (1,163,655)
                                                         -------------------   --------------    -----------------
Cancellation of shares                                           (6,275,231)            (628)                 628
Net income (loss) for the year                                            -                -                    -
                                                         -------------------   --------------    -----------------
Balance as of  December 31, 2009                                  3,731,772              373           (1,163,027)
                                                         -------------------   --------------    -----------------
Net income (loss) for the year                                            -                -                    -
                                                         -------------------   --------------    -----------------
Balance as of December 31, 2010                                   3,731,772              373           (1,163,027)
                                                         -------------------   --------------    -----------------
Net income (loss) for the year                                            -                -                    -
                                                         -------------------   --------------    -----------------
Balance as of December 31, 2011                                   3,731,772              373           (1,163,027)
                                                         -------------------   --------------    -----------------
Net income (loss) for the year                                            -                -                    -
                                                         -------------------   --------------    -----------------
Balance as of December 31, 2012                                   3,731,772              373           (1,163,027)
                                                         ------------------------------------------------------------
Convertible Promissory Note Discount                                      -                -               69,000
Net income (loss) for the period                                          -                -                    -
                                                         -------------------   --------------    -----------------
Balacne as of March 31, 2013                                      3,731,772            $ 373          $(1,094,027)
                                                         ===================   ==============    =================

* As restated for reverse merger on July 18, 2008

     See the accompanying notes to these consolidated financial statements.

</TABLE>

                                      F-3
<PAGE>
<TABLE>
<CAPTION>



                 LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
                                   (Unaudited)




(continued)
<S>                                                                             <C>


                                                          Deficit accum
                                                             During
                                                           Development
                                                              Stage              Totals
                                                       ----------------    ----------------

Balances at December 31, 2006*                                     $ -                 $ -
Net income (loss) for the year                                       -                   -
                                                       ----------------    ----------------
Balances at December 31, 2007*                                       -                   -

Issuance of Founders common stock - cash                             -               5,600
Issuance of Founders common stock - services                         -               4,200
Stock issued for Net Liabilities - reverse merger                    -          (1,197,454)
Capital contribution - related party                                 -              25,000
Net income (loss) for the year                                 (98,782)            (98,782)
                                                       ----------------    ----------------
Balance as of  December 31, 2008*                              (98,782)         (1,261,436)
                                                       ----------------    ----------------
Cancellation of shares                                               -                   -
Net income (loss) for the year                                (155,673)           (155,673)
                                                       ----------------    ----------------
Balance as of  December 31, 2009                              (254,455)         (1,417,109)
                                                       ----------------    ----------------
Net income (loss) for the year                                (125,970)           (125,970)
                                                       ----------------    ----------------
Balance as of December 31, 2010                               (380,425)         (1,543,079)
                                                       ----------------    ----------------
Net income (loss) for the year                                (137,719)           (137,719)
                                                       ----------------    ----------------
Balance as of December 31, 2011                               (518,144)         (1,680,798)
                                                       ----------------    ----------------
Net income (loss) for the year                                (177,218)           (177,218)
                                                       ----------------    ----------------
Balance as of December 31, 2012                               (695,362)         (1,858,016)
                                                      -------------------------------------
Convertible Promissory Note Discount                                 -              69,000
Net income (loss) for the period                              (102,801)           (102,801)
                                                       ----------------    ----------------
Balacne as of March 31, 2013                                $ (798,163)       $ (1,891,817)
                                                       ================    ================
</TABLE>


* As restated for reverse merger on July 18, 2008

     See the accompanying notes to these consolidated financial statements.

                                      F-4
<PAGE>
<TABLE>
<CAPTION>


                 LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)

                                   May 8, 2008
<S>                                                                             <C>

                                                                         For the Three Months Ended         (Inception) to
                                                                                March 31,                      March 31,
                                                                           2013               2012               2013
                                                                      ---------------    ---------------    ---------------

Cash Flows from Operating Activities:
         Net Loss                                                         $ (102,801)         $ (44,434)        $ (798,163)
Adjustment to net loss for non-cash items:
         Finance cost of convertible promissory notes                         69,000                                69,000

Adjustments to reconcile net loss to net cash used
         in operating  activities from
         continuing operations:
         Gain on debt relief                                                       -                  -            (68,005)
         Compensatory Stock issuance                                               -                  -              4,200
         Changes in operating assets and liabilities:
           Increase in Accounts Payable and Accrued Liabilities               33,789             44,434            689,001
                                                                      ---------------    ---------------    ---------------

Net Cash Provided (Used) by Operating Activities                                 (12)                 -           (103,967)
                                                                      ---------------    ---------------    ---------------


Cash Flows from Investing Activities:

Net Cash Provided by Investing Activities                                          -                  -                  -
                                                                      ---------------    ---------------    ---------------

Cash Flows from Financing Activities:
         Capital contribution for related parties                                  -                  -             25,000
         Sale of common stock                                                      -                  -              5,600
         Funds from convertible promissory notes                              44,000                                44,000
         Payment of advance payables                                          (2,500)                               (2,500)
         Proceeds from advance payables                                            -                  -             68,956
                                                                      ---------------    ---------------    ---------------
Net Cash Provided (used) by Financing Activities                              41,500                  -            141,056
                                                                      ---------------    ---------------    ---------------
Net  Increase in Cash                                                         41,488                  -             37,089

Cash and Cash Equivalents - Beginning of Period                                   70                  -              4,499
                                                                      ---------------    ---------------    ---------------
Cash and Cash Equivalents - End of Period                                   $ 41,588                $ -           $ 41,588
                                                                      ===============    ===============    ===============

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
         Cash paid for interest expense                                          $ -                  -                  -
                                                                      ===============    ===============    ===============
         Cash paid for income taxes                                              $ -                  -                  -
                                                                      ===============    ===============    ===============


SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING
        AND FINANCING ACTIVITIES:
         Common shares issued in reverse merger                                  $ -                $ -       $ (1,197,454)
                                                                      ===============    ===============    ===============

See the accompanying notes to these consolidated financial statements.


</TABLE>
                                      F-5

<PAGE>


                 LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY
                        (A Development Stage Enterprises)
                 Notes to the Consolidated Financial Statements
                    For the Three Months Ended March 31, 2013
                                   (Unaudited)

NOTE 1.  Business, Basis of Presentation and Significant Accounting Policies:

Business:

Legacy   Technology   Holdings,   Inc.  (the  "Company"   and/or  "Legacy")  was
incorporated in Colorado in January, 1997. The Company was originally named Life
USA,  Inc. On May 20, 2008,  the Company  changed its name to Legacy  Technology
Holdings,  Inc.  by filing an  amendment  to its Article of  Incorporation.  The
Company was organized to engage in any activity or business not in conflict with
the laws of the State of  Colorado  or of the  United  States of  America.  As a
result of the name change, the Company's trading symbol on the  Over-the-Counter
Bulletin Board was changed to "LTHO".

Neuro Nutrition, the Company's wholly owned subsidiary, was incorporated on July
23, 2004 in the State of Colorado, and has no operational activities.

World Peace, the Company's wholly owned subsidiary was incorporated in the State
of  Colorado  on May 8, 2008 and has had no  operational  activities  during the
three months ended March 31, 2013 nor during the year ended December 31, 2012.

Basis of Presentation:

Development Stage Enterprise

The Company has not earned any significant revenues from its limited operations.
Accordingly,  the  Company's  activities  have been  accounted for as those of a
"Development  Stage Enterprise"  Among the disclosures  required by are that the
Company's  financial  statements be  identified as those of a development  stage
company,  and that the statements of operation,  stockholders'  equity (deficit)
and cash flows disclose activity since the date of the Company's inception.

Principles of Consolidation

The  accompanying  consolidated  financial  statements  include the  accounts of
Legacy and its  wholly-owned  subsidiaries,  Neuro  Nutrition,  Inc.  and Legacy
Technology  Holdings (formerly World Peace  Technologies,  Inc.) All significant
inter-company balances and transactions have been eliminated in consolidation.

Significant Accounting Policies:

Cash and Cash Equivalents

The Company  maintains the majority of its cash  accounts at a commercial  bank.
The total cash balance is insured by the Federal Deposit  Insurance  Corporation
("FDIC") up to $100,000 per  commercial  bank. As of March 31, 2013 and December
31, 2012, the Company had zero amounts in excess of the FDIC insured limits. For
purposes of the  statement  of cash flows,  the Company  considers  all cash and
highly liquid  investments with initial maturities of three months or less to be
cash equivalents.

                                      F-6
<PAGE>




Estimates

The preparation of financial statements in conformity with accounting principles
generally  accepted in the United States  requires  management to make estimates
and assumptions that affects the reported amounts of assets and liabilities, and
disclosure of  contingent  assets and  liabilities  at the date of the financial
statements and the reported amounts of revenue and expenses during the reporting
period.  Such  estimates  may be  materially  different  from  actual  financial
results.  Significant  estimates include the recoverability of long-lived assets
and the collectability of accounts receivable.

Revenue Recognition

Revenue  Recognition is recognized  when earned.  Sales revenue is recognized at
the date of shipment to customers when a formal arrangement exists, the price is
fixed  or  determinable,   the  delivery  is  completed,  no  other  significant
obligations  of the Company  exist and  collectability  is  reasonably  assured.
Payments  received before all of the relevant  criteria for revenue  recognition
are satisfied are recorded as unearned revenue.

Net Loss per Share

Basic  net  loss  per  common  share  is  calculated  by  dividing  the net loss
applicable to common shares by the weighted  average number of common and common
equivalent  shares  outstanding  during the period.  For the three  months ended
March 31, 2013 and 2012, there were no potential common  equivalent  shares used
in the calculation of weighted  average common shares  outstanding as the effect
would be anti-dilutive because of the net loss.

Stock-Based Compensation

The Company adopted the provisions of and accounts for stock-based  compensation
using an estimate of value in accordance  with the fair value method.  Under the
fair value recognition  provisions of this statement,  stock-based  compensation
cost is  measured  at the grant date based on the fair value of the award and is
recognized  as  expense on a  straight-line  basis  over the  requisite  service
period,  which  generally  is  the  vesting  period.  The  Company  elected  the
modified-prospective  method,  under  which  prior  periods  are not revised for
comparative  purposes.  The valuation method applies to new grants and to grants
that were outstanding as of the effective date and are subsequently modified.

Fair Value of Financial Instruments

The  carrying  amount  of  accounts  payable,   accrued  expenses,   convertible
promissory  notes are considered to be  representative  of their respective fair
values because of the short-term nature of these financial instruments.

Other Comprehensive Income

The Company has no material components of other comprehensive  income (loss) and
accordingly, net loss is equal to comprehensive loss in all periods.

                                      F-7
<PAGE>




Income Taxes

Provision for income taxes represents actual or estimated amounts payable on tax
return filings each year.  Deferred tax assets and  liabilities are recorded for
the estimated future tax effects of temporary  differences between the tax basis
of assets and  liabilities  and  amounts  reported in the  accompanying  balance
sheets,  and for  operating  loss and tax credit carry  forwards.  The change in
deferred  tax assets and  liabilities  for the period  measures the deferred tax
provision  or benefit for the period.  Effects of changes in enacted tax laws on
deferred  tax assets and  liabilities  are  reflected as  adjustment  to the tax
provision or benefit in the period of enactment.

Recent Accounting Pronouncements

There were various other accounting standards and interpretations  issued during
the three  months  ended March 31,  2013,  none of which are  expected to have a
material impact on the Company's financial position, operations or cash flows.

NOTE 2.   Going Concern:

The  Company's  financial  statements  for the three months ended March 31, 2013
have been prepared on a going concern basis,  which contemplates the realization
of assets and the settlement of liabilities and commitments in the normal course
of  business.  The Company  reported a net loss of $102,801 for the three months
ended March 31,  2013,  and an  accumulated  deficit of $798,163 as of March 31,
2013.  At  March  31,  2013,  the  Company  had a  working  capital  deficit  of
$1,891,817.

The future  success of the Company is likely  dependent on its ability to attain
additional  capital,  or to find an  acquisition  to add  value  to its  present
shareholders  and  ultimately,  upon its  ability  to attain  future  profitable
operations.  There can be no assurance  that the Company will be  successful  in
obtaining  such  financing,  or that it will  attain  positive  cash  flow  from
operations. Management believes that actions presently being taken to revise the
Company's operating and financial  requirements  provide the opportunity for the
Company to continue as a going concern.

NOTE 3.  Notes Payable:

         The Company's  outstanding  non-convertible  notes payable on March 31,
2013 and 2012, consisted of:

   $ 15,080         Note Payable issued to an investor. Due upon demand.
                    Interest rate is 8%

     10,353         Note payable, issued to vendor.  Due upon demand

      6,199         Other notes payable
     --------
   $ 31,632         Total notes payable outstanding on March 31, 2013 and
                    December 31, 2012.
     ========

                                      F-8
<PAGE>





<PAGE>

NOTE 4.  Convertible Notes Payable:

Convertible  notes  payable as of December  31, 2011 and 2010  consisted  of the
following:

         $ 50,000      Note payable 1, convertible into 151,515 shares with
                       conversion feature expiring in May 2008,
                       due September 30, 2006, incurring interest at 25%,
                       attached to the note are 151,515 warrants exercisable
                       at $0.625 per share, which expired in 2008. The note
                       is secured by a subordinated pledge of inventory and
                       accounts receivable.

         $ 25,000      Note payable 2, convertible into 50,000 shares of Neuro
                       Nutrition, Inc. with conversion feature expiring at
                       end 2007, due September 7, 2006, incurring interest
                       at 10%.

         $ 50,000      Note payable 1, convertible into 151,515 shares with
                       conversion feature expiring in May 2008,
                       due September 30, 2006, incurring interest at 25%,
                       attached to the note are 151,515 warrants exercisable
                       at $0.625 per share, which expired in 2008. The note
                       is secured by a subordinated pledge of inventory and
                       accounts receivable.

         $ 75,000      Note payable 4, convertible into 227,273 shares with
                       conversion feature expiring in May 2008,
                       due September 30, 2006, incurring interest at 25%,
                       attached to the note are 227,273 warrants exercisable
                       at $0.625 per share, which expired in 2008. The note
                       is secured by a subordinated pledge of inventory and
                       accounts receivable.

         $ 20,000      Note payable 5, convertible into 40,000 shares of Neuro
                       Nutrition, Inc. anytime at Holder's option, due
                       February 28, 2007, incurring interest at 20%,attached
                       to the note are  40,000  warrants  for Neuro
                       Nutrition,  Inc. common stock exercisable at
                       $0.65 per share.

         $ 50,000      Note payable 6, convertible into 100,000 shares of
                       Neuro Nutrition, Inc. anytime at Holder's option, due
                       February 28, 2007,  incurring  interest at 20%, attached
                       to the note are 100,000 warrants for Neuro Nutrition,
                       Inc. common stock exercisable at $0.65 per share.

         $ 75,000      Note payable 7, convertible into 150,000 shares of
                       Neuro Nutrition, Inc. with conversion feature
                       expiring in May 2008, due May 27, 2006, incurring
                       interest at 10%, attached to the note are 150,000
                       warrants for Neuro Nutrition, Inc. exercisable at $0.625
                       per share, which expired in 2008.

                                      F-9

<PAGE>




         $ 50,000      Note payable 8, convertible into 100,000 shares with
                       conversion feature expiring in November 2008, due
                       November 11, 2006, incurring interest at 10%, attached to
                       the note are 200,000  warrants  exercisable at $0.625 per
                       share, which expired in 2008.

         $ 50,000      Note payable 8, convertible into 100,000 shares with
                       conversion feature expiring in November 2008, due
                       November 11, 2006, incurring interest at 10%, attached to
                       the note are 200,000  warrants  exercisable at $0.625 per
                       share, which expired in 2008.

         $  5,000      Note payable 10, convertible into 10,000 shares with
                       conversion feature expiring in November 2008, due
                       November 11, 2006, incurring interest at 10%, attached to
                       the note are 20,000  warrants  exercisable  at $0.625 per
                       share, which expired in 2008.

         $ 50,000     Note payable 11, convertible into 100,000 shares anytime
                      at Holder's option, due December 7, 2006, incurring
                      interest at 10%, attached to the note are 200,000
                      warrants exercisable at $0.625 per share, which
                      expired in 2008.

         $ 25,000      Note payable 12, convertible into 50,000 shares anytime
                       at Holder's option, due February 20, 2007, incurring
                       interest at 10%, attached to the note are 100,000
                       warrants exercisable at $0.75 per share, which
                       expired in 2008.

         $  5,000      Note payable 13, convertible into 10,000 shares anytime
                       at Holder's option, due February 28, 2007, incurring
                       interest at 10%, attached to the note are 20,000
                       warrants exercisable at $0.75 per share, which
                       expired in 2008.

         $ 50,000      Note payable 14, convertible into 125,000 shares
                       anytime at Holder's option, due September 12, 2006,
                       incurring interest at 25%, attached to the note are
                       250,000 warrants exercisable at $0.75 per share,
                       which expired in 2008. This note is secured by
                       inventory and accounts receivable.

         $ 50,000      Note payable 15, convertible into 125,000 shares anytime
                       at Holder's option,  due September 12, 2006,
                       incurring  interest  at 25%,  attached to the
                       note  are  250,000  warrants  exercisable  at
                       $0.75 per share,  which expired in 2008. This
                       note is secured by inventory and accounts receivable.
         --------
         $630,000     Total Convertible notes payable. All these notes, with
         ========     the exception of notes 1, 3, 4, 14 and 15 are unsecured.


As of March  31,  2013,  all of the  convertible  notes  described  above are in
default.

                                      F-10
<PAGE>


In March 31, 2013, the Company issued an unsecured  convertible  promissory note
in exchange for cash of $44,000.  In addition,  the Company  issued an unsecured
convertible  promissory  note in exchange  for already  outstanding  advances of
$25,000.  The  convertible  promissory  notes have a term of 1 year, an interest
rate of 8% per annum and provides for the  conversion of the note into shares of
the  Company's  common  stock at $0.07 per share.  The Company has  recognized a
finance cost of $69,000 in connection with the convertible promissory notes.

NOTE 5.  Stock Options and Warrants:

At March 31,  2013,  the  Company  had stock  option  and  warrant  activity  as
described below.

Non-employee stock options

The Company  accounts for  non-employee  stock  options  under ASC 718,  whereby
option costs are recorded based on the fair value of the consideration  received
or the fair value of the equity instruments  issued,  whichever is more reliably
measurable.  Unless otherwise  provided for, the Company covers option exercises
by issuing new shares.

The  Company's  subsidiary  Neuro  Nutrition,  Inc. at the beginning of 2010 had
140,000  common  stock  purchase  warrants  outstanding.  The warrants are to be
effectively  granted for exercise upon  conversion  by the warrant  holder of an
accompanying  note  payable  into common  stock,  which said note the holder can
convert anytime at his option.  The warrant holder has two years after effective
grant date to exercise  the  warrants,  at a price of $.625 per share.  No Neuro
Nutrition,  Inc.  warrants  were  exercised  or expired  during the three months
ended, leaving a balance of 140,000 warrants at March 31, 2013.

Employee stock options

The Company  accounts for employee stock options under ASC 718. Unless otherwise
provided for, the Company covers option  exercises by issuing new shares.  There
were no employee stock options issued or outstanding at March 31, 2013.

NOTE 6.   Taxes:

The Company is subject to foreign and domestic income taxes. The Company has had
no income, and therefore has paid no income tax.

                                      F-11
<PAGE>




Deferred income taxes arise from temporary timing differences in the recognition
of income and expenses for financial  reporting and tax purposes.  The Company's
deferred  tax assets  consist  entirely of the benefit from net  operating  loss
(NOL)  carry-forwards.  The NOL carry  forwards  expire in various years through
2030. The Company's deferred tax assets are offset by a valuation  allowance due
to  the  uncertainty  of  the  realization  of  the  NOL   carry-forwards.   NOL
carry-forwards may be further limited by a change in company ownership and other
provisions of the tax laws.

The Company's deferred tax assets,  valuation allowance, and change in valuation
allowance are as follows:

                         Estimated NOL
                         Carry-forward      Valuation     Net Tax
     Period Ending          benefit         Allowance     Benefit

    March 31, 2013           $163,579        $(163,579)       -



                         Estimated NOL
                         Carry-forward      Valuation      Net Tax
     Period Ending          benefit         Allowance      Benefit

   December 31, 2012         $139,072      $(139,072)          -


NOTE 7 - Legal Proceedings:

In May 2008 a  complaint  was  filed in the  District  Court  for the  County of
Boulder, Colorado by product suppliers of the Company (the "Plaintiffs") seeking
collection  of trade  accounts due in the  approximate  amount of $127,000  plus
collection  costs.  Research of the account by Plaintiff's  counsel  effectively
reduced this amount to approximately $64,000, which is included in the Company's
balance sheet liabilities. The case is ongoing at the present time.

NOTE 8 - Subsequent Events:

On  April  4,  2013,   the  Company   entered  into  a  Plan  and  Agreement  of
Reorganization  and Share  Exchange  Agreement  ("the  Agreement")  with Genomic
Integrated Wellness Systems, Inc. ("GIWS") and GIWS's sole shareholder,  Charles
Youngren.

                                      F-12

<PAGE>





The  Agreement  provides  for the  Company  to issue  22,527,088  shares  of its
restricted  common stock to be exchanged for 100% of the issued and  outstanding
equity of GIWS,  making the Company the sole shareholder of GIWS. As a result of
the issuance,  the sole shareholder of GIWS, Charles Youngren,  will hold 80% of
the issued and outstanding common stock of the Company, post-acquisition.

Closing of the acquisition is contingent upon the delivery of audited  financial
statements by GIWS.

                                      F-13

<PAGE>




ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

The  following  discussion  should  be read in  conjunction  with our  unaudited
financial  statements and notes thereto included herein. In connection with, and
because we desire to take  advantage  of, the "safe  harbor"  provisions  of the
Private  Securities  Litigation Reform Act of 1995, we caution readers regarding
certain forward looking statements in the following  discussion and elsewhere in
this report and in any other statement made by, or on our behalf, whether or not
in future filings with the Securities and Exchange  Commission.  Forward-looking
statements are statements not based on historical  information  and which relate
to future  operations,  strategies,  financial  results  or other  developments.
Forward looking  statements are necessarily based upon estimates and assumptions
that are inherently  subject to significant  business,  economic and competitive
uncertainties and  contingencies,  many of which are beyond our control and many
of which,  with  respect to future  business  decisions,  are subject to change.
These  uncertainties and contingencies can affect actual results and could cause
actual results to differ  materially from those expressed in any forward looking
statements  made by, or on our behalf.  We  disclaim  any  obligation  to update
forward-looking statements.

The  independent  registered  public  accounting  firm's report on the Company's
financial  statements as of December 31, 2012,  and for each of the years in the
two-year period then ended,  includes a "going concern"  explanatory  paragraph,
that describes  substantial  doubt about the Company's  ability to continue as a
going concern.

PLAN OF OPERATIONS
------------------

We had we had no revenues  during the three months ended March 31, 2013. We have
minimal capital,  minimal cash, and only our intangible assets consisting of our
business  plan,  relationships  and  contacts.  We are  illiquid  and need  cash
infusions from investors or shareholders to provide  capital,  or loans from any
sources.

The Company has focused its efforts, since July of 2009, has focused its efforts
on the completion of its past due audits and the filing of its financial reports
with the Securities and Exchange Commission (SEC). As we have come closer to the
completion  of such  efforts,  the Company has begun to focus its efforts on the
development of operations through an acquisition.

On  April  4,  2013,   the  Company   entered  into  a  Plan  and  Agreement  of
Reorganization  and Share  Exchange  Agreement  ("the  Agreement")  with Genomic
Integrated Wellness Systems, Inc. ("GIWS") and GIWS's sole shareholder,  Charles
Youngren.

The  Agreement  provides  for the  Company  to issue  22,527,088  shares  of its
restricted  common stock to be exchanged for 100% of the issued and  outstanding
equity of GIWS,  making the Company the sole shareholder of GIWS. As a result of
the issuance,  the sole shareholder of GIWS, Charles Youngren,  will hold 80% of
the issued and outstanding common stock of the Company, post-acquisition.

Closing of the acquisition is contingent upon the delivery of audited  financial
statements  by GIWS.  In  addition,  at closing,  the  existing  officers of the
Company  will  resign  and  new  officers  will  be  appointed  by  GIWS's  sole
shareholder.  Mr. Youngren will be appointed the Chief  Operating  Officer and a
director of the Company.  In addition,  as, the sole  shareholder  of GIWS,  Mr.
Youngren  will have the ability to appoint two new  directors  to the  Company's
Board of Directors.

                                       1

<PAGE>




GIWS was  incorporated  on November 15, 2012 in the state of  Colorado,  but has
operations in Hawaii.  GIWS was formed in order to develop and  commercialize  a
web-based  genomic  preventative   medicine  solution  using  sophisticated  and
proprietary  algorithms to analyze data, on individual patient lifestyle factors
such as  biometrics,  diet,  pharmaceuticals,  endocrine  and blood  tests,  and
genetic  markers.  The aggregation of this Patient data in a Data Warehouse will
facilitate analysis via a variety of Machine Learning  Algorithms.  Discovery of
Genetic Marker  patterns,  endocrine and blood  analysis  detected  trends,  and
associations   with  individual   Patient  factors  can  facilitate   customized
Individual Patient  Preventative  Medicine solutions by health  professionals to
mitigate the expression of undesirable  Genetic  characteristics  and to enhance
the expression of desirable Genetic characteristics.

We will need  substantial  additional  capital to support our proposed  business
acquisition.  We have no revenues.  We have no committed source for any funds as
of date here. No  representation  is made that any funds will be available  when
needed.  In the event funds cannot be raised when needed,  we may not be able to
carry out our business  plan,  may never  achieve sales or royalty  income,  and
could fail in business as a result of these uncertainties.

RESULTS OF OPERATIONS
---------------------

For the Three  Months  Ended March 31, 2013  Compared to the Three  Months Ended
March 31, 2013

During the three months ended March 31, 2013 and 2012,  we did not recognize any
revenues from our operations. We do not expect to recognize revenues in the near
future,  as we work to complete our proposed  acquisition  with GIWS,  discussed
above.

During  the  three  months  ended  March  31,  2013,  we  incurred  general  and
administrative  expenses of $5,933  compared to $16,657  during the three months
ended March 31, 2013.  The decrease of $10,724 was a result of decrease in legal
fees as the Company has neared the  completion  of the work to bring its filings
current.

During  the  three  months  ended  March 31,  2013,  we  incurred  a net loss of
$102,801,  compared to $44,434 during the three months ended March 31, 2012. The
increase  of  $58,367  is a  result  of the  $10,724  decrease  in  general  and
administrative expenses,  offset by a $69,091 increase in other income (expense)
resulting from the $69,000 finance cost recognized in connection with $69,000 in
convertible promissory notes issued by the Company during the three months ended
March 31, 2013.

LIQUIDITY
---------

We have nominal  cash of $41,558 and no other  liquid  assets at March 31, 2013,
and we will be reliant upon shareholder loans or private placements of equity to
fund any kind of  operations.  We have  secured  no  sources of loans or private
placements at this time.

During  the three  months  ended  March 31,  2013,  we used  funds of $12 in our
operational  activities.  During  the three  months  ended  March 31,  2013,  we
recognized  a net loss of $102,801,  which was adjusted for the $69,000  finance
cost  incurred  in  connection  with  the  Company's   issuance  of  $69,000  in
convertible promissory notes during the three months ended March 31, 2013..

During the three  months  ended March 31,  2012,  we did not receive or use cash
from our operational  activities.  During the three months ended March 31, 2012,
we recognized a net loss of $44,434 and did not have any non-cash adjustments to
net losses.

During the three months ended March 31, 2013 and 2012, we did not use or receive
any funds from investment activities.

                                       2
<PAGE>





During the three months ended March 31, 2013, we received  funds of $41,500 from
our financing  activities.  During the three months ended March 31, 2012, we did
not receive or use any funds from our financing activities.

In March 31, 2013, the Company issued an unsecured  convertible  promissory note
in exchange for cash of $44,000.  In addition,  the Company  issued an unsecured
convertible  promissory  note in exchange  for already  outstanding  advances of
$25,000.  The  convertible  promissory  notes have a term of 1 year, an interest
rate of 8% per annum and provides for the  conversion of the note into shares of
the  Company's  common  stock at $0.07 per share.  The Company has  recognized a
finance cost of  $69,000 in connection with the convertible promissory notes.

Short Term.

On a  short-term  basis,  Legacy  has not  generated  any  revenue  or  revenues
sufficient  to cover  operations.  For  short  term  needs the  Company  will be
dependent on receipt, if any, of offering proceeds.

Capital Resources

The Company has only common stock as its capital resource.

Legacy has no  material  commitments  for capital  expenditures  within the next
year, however if operations are commenced, substantial capital will be needed to
pay for  participation,  investigation,  exploration,  acquisition  and  working
capital.

Need for Additional Financing

Legacy does not have capital sufficient to meet its cash needs. The Company will
have to seek  loans or  equity  placements  to cover  such  cash  needs.  Once a
business acquisition is completed,  the Company's needs for additional financing
is likely to increase substantially.

No  commitments  to provide  additional  funds  have been made by the  Company's
management or other  stockholders.  Accordingly,  there can be no assurance that
any  additional  funds  will be  available  to  Legacy  to allow it to cover the
Company's expenses as they may be incurred.


ITEM 3.  QUANTATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable

ITEM 4.  CONTROLS AND PROCEDURES

The Company  maintains a system of disclosure  controls and procedures  that are
designed for the purposes of ensuring that information  required to be disclosed
in the Company's SEC reports is recorded,  processed,  summarized,  and reported
within the time  periods  specified  in the SEC rules and  forms,  and that such
information  is  accumulated  and  communicated  to  the  Company's  management,
including the Chief Executive  Officer as appropriate to allow timely  decisions
regarding required disclosure.

                                       3
<PAGE>




Management,  after  evaluating  the  effectiveness  of the Company's  disclosure
controls and  procedures as defined in Exchange Act Rules  13a-14(c) as of March
31, 2013 (the  "Evaluation  Date") concluded that as of the Evaluation Date, the
Company's  disclosure  controls  and  procedures  were  effective to ensure that
material  information  relating  to the  Company  would be made known to them by
individuals within those entities,  particularly during the period in which this
annual report was being prepared and that  information  required to be disclosed
in the Company's SEC reports is recorded,  processed,  summarized,  and reported
within the time periods specified in the SEC's rules and forms.

MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING.

Legacy's  management is responsible for  establishing  and maintaining  adequate
internal control over financial  reporting for the company in accordance with as
defined in Rules  13a-15(f) and 15d-15(f)  under the Exchange Act. The Company's
internal  control over  financial  reporting  is designed to provide  reasonable
assurance  regarding the reliability of financial  reporting and the preparation
of financial  statements  for external  purposes in  accordance  with  generally
accepted  accounting  principles.  The Company's internal control over financial
reporting includes those policies and procedures that:

(1)      pertain to the  maintenance  of records that,  in reasonable  detail,
         accurately  and fairly  reflect the transactions and dispositions of
         the Company's assets;

(2)      provide   reasonable   assurance  that  transactions  are  recorded  as
         necessary to permit  preparation of financial  statements in accordance
         with generally accepted accounting  principles,  and that the Company's
         receipts  and  expenditures  are  being  made only in  accordance  with
         authorizations of Legacy's management and directors; and

(3)      provide reasonable  assurance regarding  prevention or timely detection
         of unauthorized acquisition, use or disposition of the Company's assets
         that could have a material effect on Legacy's financial statements.

Management's  assessment  of  the  effectiveness  of the  registrant's  internal
control over financial  reporting is as of March 31, 2013. The Company  believes
that internal control over financial reporting is ineffective,  due to a lack of
accounting  staff.  The  Company  does not have the  financial  ability  to hire
additional accounting staff, at this time.

Because of its inherent  limitations,  internal control over financial reporting
may not prevent or detect misstatements.  Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become
inadequate  because of changes in  conditions,  or that the degree of compliance
with the policies or procedures may deteriorate.

This report does not include an attestation  report of the Company's  registered
public  accounting  firm regarding  internal  control over financial  reporting.
Management's  report was not subject to attestation by the Company's  registered
public  accounting  firm  pursuant  to  temporary  rules of the  Securities  and
Exchange  Commission that permit the Company to provide only management's report
in this annual report.

There was no change in the Company's  internal control over financial  reporting
that  occurred  during the fiscal  quarter ended  September  30, 2012,  that has
materially affected,  or is reasonably likely to materially affect, its internal
control over financial reporting.

                                       4
<PAGE>



                           PART II. OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

                NONE.

ITEM 1A.  RISK FACTORS

            Not Applicable to Smaller Reporting Companies.

ITEM 2.  CHANGES IN SECURITIES

During the period of January 1, 2013  through  March 31,  2013,  the Company has
made the following unregistered issuances of its securities.

<TABLE>
<CAPTION>
<S>                                                                             <C>

        DATE OF SALE            TITLE OF SECURITIES     NO. OF SHARES         CONSIDERATION          CLASS OF PURCHASER
------------------------------ ----------------------- ----------------- ------------------------- -----------------------
         March 2013            Convertible                    -                  $44,000             Business Associate
                               Promissory Note
         March 2013            Convertible                    -              $25,000 Advance         Business Associate
                               Promissory Note                                   Payable
</TABLE>

Exemption From Registration Claimed

All of the above sales by the Company of its  unregistered  securities were made
by the Company in reliance upon Section 4(2) of the  Securities  Act of 1933, as
amended (the "1933 Act"). All of the individuals  and/or entities that purchased
the unregistered  securities were primarily existing shareholders,  known to the
Company and its management, through pre-existing business relationships, as long
standing business associates and employees.  All purchasers were provided access
to all material information, which they requested, and all information necessary
to verify such information and were afforded access to management of the Company
in  connection  with  their  purchases.   All  purchasers  of  the  unregistered
securities  acquired such  securities  for investment and not with a view toward
distribution,  acknowledging  such intent to the Company.  All  certificates  or
agreements  representing such securities that were issued contained  restrictive
legends,   prohibiting  further  transfer  of  the  certificates  or  agreements
representing  such  securities,  without  such  securities  either  being  first
registered  or  otherwise  exempt from  registration  in any  further  resale or
disposition.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

                NONE.

ITEM 4.  MINE AND SAFETY DISCLOSURE

            Not Applicable

ITEM 5.  OTHER INFORMATION

              NONE.

                                       5

<PAGE>





ITEM 6.  EXHIBITS

Exhibits.  The  following is a complete  list of exhibits  filed as part of this
Form 10-Q.  Exhibit  numbers  correspond  to the numbers in the Exhibit Table of
Item 601 of Regulation S-K.

     Exhibit  31.1  Certification  of  Chief  Executive  Officer  and  Principal
     Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act

     Exhibit 32.1  Certification  of Principal  Executive and Financial  Officer
     pursuant to Section 906 of the Sarbanes-Oxley Act

                                       6

<PAGE>



                                   SIGNATURES


     Pursuant to the  requirements  of Section 12 of the Securities and Exchange
Act of 1934,  the  Registrant  has duly  caused  this report to be signed on its
behalf by the undersigned, thereunto duly authorized.





                                              LEGACY TECHNOLOGY HOLDINGS, INC.
                                                      (Registrant)



Dated:   July 1, 2013             By: /s/Redgie Green
                                      ------------
                                      Redgie Green (Principal Executive Officer,
                                      President and Chief Executive Officer)

                                       7